nivolumab,cc-122,cc-99282,durvalumab,ibrutinib,cc-220,relatlimab
janssen,astrazeneca,immunocore,abbvie,bms
['platform', '$imcr']
$imcr data maybe aren't the best, but not bad either. still early to tell, and recist isn't the only measure for clinical benefit. good to see no major toxicity. this is further validation of the platform. #esmo22
Biotech research.

Become a Patron: https://t.co/hU9yYMhRDd